CRISPR Therapeutics
CRSP
CRSP
432 hedge funds and large institutions have $4.68B invested in CRISPR Therapeutics in 2025 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 146 increasing their positions, 118 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
13% more call options, than puts
Call options by funds: $307M | Put options by funds: $271M
1% more funds holding
Funds holding: 429 → 432 (+3)
4.37% less ownership
Funds ownership: 83.78% → 79.42% (-4.4%)
Holders
432
Holding in Top 10
7
Calls
$307M
Puts
$271M
Top Buyers
| 1 | +$144M | |
| 2 | +$64.1M | |
| 3 | +$63.8M | |
| 4 |
Morgan Stanley
New York
|
+$57.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$47.7M |
Top Sellers
| 1 | -$50M | |
| 2 | -$47M | |
| 3 | -$46.9M | |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$34.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$32.7M |
